They already have a baseline for dosages from the

They already have a baseline for dosages from the Brilacidin-UP study. It's reasonable to start from there.

Remember that with ANY drug, you want to keep the doses in a range where it is efficacious, but not so large that you risk having side effects.

Brilacidin's initial problem with PolyMedix running the clinical trial was that they used massive doses which DID cause side effects. In the much smaller yet efficacious doses that CTIX/IPIX used, there were no significant side effects. The transient finger tingling when they did the ABSSSI study resolved quickly, and many drugs that have been approved have very serious side effects, like death, so by comparison finger-tingling for a day or two is insignificant. Since there seems to be no systemic absorption from the time-release pill, the tingling side effect should not be an issue. But, why give someone more medication than they need?

I think that IPIX started with such tiny doses in the Kevetrin trial because of the lesson of giant-dose Brilacidin -- just about anything in a large dose can be bad. Tylenol causes liver damage when taken daily, even in normal doses over a long period of time. Aspirin can kill you (and even just fairly large non-fatal doses can cause very significant blood thinning -- hence the low-dose daily pill for heart patients). The less drug you can use, the better.